Objective
to compare the safety and efficacy of the Edwards PASCAL vs Abbott MitraClip systems for treating degenerative mitral regurgitation (DMR)
Study
combined data from CLASP IID randomised, open-label, non-inferiority trial and the additional observational registry
Population
patients with DMR who are anatomically suitable for mitral valve edge-to-edge with either system (RCT) or those with complex anatomy deemed ineligible for randomisation (registry)
Endpoints
Safety: major adverse events (mortality, CV mortality, HF hospitalisation, unplanned MV intervention); efficacy: MR reduction, changes in quality of life via KCCQ score
Conclusion
PASCAL mitral edge-to-edge repair achieved significant and sustained MR reduction and quality-of-life improvements at 24-month follow-up when treating a broad population of DMR patients.
Makkar et al. JACC Cardiovasc Interv. 2025 Oct 13.